Biodel announces schedule for presentations at 70th Scientific Sessions of American Diabetes Association

Biodel Inc. (Nasdaq: BIOD) announced today that the following oral and poster presentations describing results from studies of the company's product candidates will be presented during the 70th Scientific Sessions of the American Diabetes Association this month in Orlando, Florida:

Oral Presentation:

#36-OR, Oral Session on Insulin Therapy, June 25, 5pm, "An Open-Label Multicenter Trial of VIAject® vs. Regular Human Insulin in Patients With Type 2 Diabetes: Final Analyses"; presented by Helena Rodbard, MD, Endocrine and Metabolic Consultants, LLC

Poster Presentations:

#1411-P, Category 15-C, June 26, 11:30am, "Pharmacokinetics and Pharmacodynamics of a New Rapid Acting Insulin Formulation 'Vialog' in the Diabetic Swine Model"; presented by Roderike Pohl, PhD, Biodel Inc.

#642-P, Category 01-D, June 28, 12pm, "An Open-Label, Multicenter Trial of VIAject® vs. Regular Human Insulin in Patients with Type 1 Diabetes: Impact of Regional Differences on Efficacy Analyses"; presented by Priscilla Hollander, MD, Baylor University Medical Center

#622-P, Category 01-D, June 28, 12pm, "A Novel pH-Neutral Formulation of the Monomeric Insulin VIAject® Has a Faster Onset of Action Than Insulin Lispro"; presented by Tim Heise, MD, Profil Institut fur Stoffwechselforschung

The abstracts can also be accessed by registered meeting attendees through the association's web site, www.diabetes.org.